Loss of cardioprotection with ischemic preconditioning in aging hearts: Role of sirtuin 1?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 1, 2013, Pages 46-53

  Adam, Tasneem ^a   Sharp, Stephanie ^a   Opie, Lionel H ^a   Lecour, Sandrine ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

age; cardioprotection; ischemic preconditioning; Sirtuin 1

Indexed keywords

ENZYME INHIBITOR; PROTEIN INHIBITOR; RESVERATROL; SIRTUIN 1;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC PRECONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

AGING; ANIMALS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, LONG-EVANS; SIRTUIN 1;

EID: 84871547822     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248412458723     Document Type: Article

References (48)

1. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res. 2009 ; 83 (2). 247-261
2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 ; 74 (5). 1124-1136
3. Bartling B, Friedrich I, Silber RE, Simm A. Ischemic preconditioning is not cardioprotective in senescent human myocardium. Ann Thorac Surg. 2003 ; 76 (1). 105-111
4. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003 ; 425 (6954). 191-196
5. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science. 2000 ; 289 (5487). 2126-2128
6. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature. 2001 ; 410 (6825). 227-230
7. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A. 2004 ; 101 (45). 15998-16003
8. Shen M, Jia GL, Wang YM, Ma H. Cardioprotective effect of resvaratrol pretreatment on myocardial ischemia-reperfusion induced injury in rats. Vascul Pharmacol. 2006 ; 45 (2). 122-126
9. Bradamante S, Piccinini F, Barenghi L, et al. Does resveratrol induce pharmacological preconditioning?. Int J Tissue React. 2000 ; 22 (1). 1-4
10. Lamont KT, Somers S, Lacerda L, Opie LH, Lecour S. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J Pineal Res. 2011 ; 50 (4). 374-380
11. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006 ; 444 (7117). 337-342
12. Cheng HL, Mostoslavsky R, Saito S, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A. 2003 ; 100 (19). 10794-10799
13. Alcendor RR, Kirshenbaum LA, Imai S, Vatner SF, Sadoshima J. Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res. 2004 ; 95 (10). 971-980
14. Alcendor RR, Gao S, Zhai P, et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res. 2007 ; 100 (10). 1512-1521
15. Hsu CP, Zhai P, Yamamoto T, et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation. 2010 ; 122 (21). 2170-2182
16. Nadtochiy SM, Yao H, McBurney MW, et al. SIRT1-mediated acute cardioprotection. Am J Physiol Heart Circ Physiol. 2011 ; 301 (4). H1506 - H1512
17. Ebrahim Z, Yellon DM, Baxter GF. Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension. Exp Gerontol. 2007 ; 42 (8). 807-814
18. Tani M, Suganuma Y, Hasegawa H, et al. Changes in ischemic tolerance and effects of ischemic preconditioning in middle-aged rat hearts. Circulation. 1997 ; 95 (11). 2559-2566
19. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 2002 ; 34 (5). 509-518
20. Awan MM, Makaula S, Forresti S, Sack MN, Opie LH. Mechanisms whereby glucose deprivation triggers metabolic preconditioning in the isolated rat heart. Mol Cell Biochem. 2000 ; 211 (1-2). 111-121
21. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977 ; 83: 346-356
22. Abete P, Cioppa A, Calabrese C, et al. Ischemic threshold and myocardial stunning in the aging heart. Exp Gerontol. 1999 ; 34 (7). 875-884
23. Chang KC, Tsai YF, Chow CY, Peng YI, Chen TJ. Age-related changes of arterial mechanical properties in rats: analysis using exponentially tapered T-tube model. J Gerontol A Biol Sci Med Sci. 1998 ; 53 (4). B274 - B280
24. Lesnefsky EJ, Gallo DS, Ye J, Whittingham TS, Lust WD. Aging increases ischemia-reperfusion injury in the isolated, buffer-perfused heart. J Lab Clin Med. 1994 ; 124 (6). 843-851
25. Schulman D, Latchman DS, Yellon DM. Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2001 ; 281 (4). H1630 - H1636
26. Hsu CP, Odewale I, Alcendor RR, Sadoshima J. Sirt1 protects the heart from aging and stress. Biol Chem. 2008 ; 389 (3). 221-231
27. Sundaresan NR, Pillai VB, Gupta MP. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J Mol Cell Cardiol. 2011 ; 51 (4). 614-618
28. Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM. Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem. 2003 ; 278 (51). 50985-50998
29. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem. 2002 ; 277 (47). 45099-45107
30. Zhu H, Yang Y, Wang Y, Li J, Schiller PW, Peng T. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res. 2011 ; 92 (1). 75-84
31. Chen WL, Kang CH, Wang SG. Lee HM. alpha-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. Diabetologia. 2012 ; 55 (6). 1824-1835
32. Porcu M, Chiarugi A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci. 2005 ; 26 (2). 94-103
33. Mattagajasingh I, Kim CS, Naqvi A, et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2007 ; 104 (37). 14855-14860
34. Solomon JM, Pasupuleti R, Xu L, et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol. 2006 ; 26 (1). 28-38
35. Wang L, Zhang L, Chen ZB, Wu JY, Zhang X, Xu Y. Icariin enhances neuronal survival after oxygen and glucose deprivation by increasing SIRT1. Eur J Pharmacol. 2009 ; 609 (1-3). 40-44
36. Nadtochiy SM, Redman E, Rahman I, Brookes PS. Lysine deacetylation in ischaemic preconditioning: the role of SIRT1. Cardiovasc Res. 2011 ; 89 (3). 643-649
37. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem. 2007 ; 282 (9). 6823-6832
38. Tanno M, Kuno A, Yano T, et al. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem. 2010 ; 285 (11). 8375-8382
39. Shinmura K, Tamaki K, Bolli R. Impact of 6-mo caloric restriction on myocardial ischemic tolerance: possible involvement of nitric oxide-dependent increase in nuclear Sirt1. Am J Physiol Heart Circ Physiol. 2008 ; 295 (6). H2348 - H2355
40. Kawashima T, Inuzuka Y, Okuda J, et al. Constitutive SIRT1 overexpression impairs mitochondria and reduces cardiac function in mice. J Mol Cell Cardiol. 2011 ; 51 (6). 1026-1036
41. Oka S, Alcendor R, Zhai P, et al. PPARalpha-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab. 2011 ; 14 (5). 598-611
42. Tanno M, Kuno A, Horio Y, Miura T. Emerging beneficial roles of sirtuins in heart failure. Basic Res Cardiol. 2012 ; 107 (4). 273
43. Beher D, Wu J, Cumine S, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des. 2009 ; 74 (6). 619-624
44. Hu Y, Liu J, Wang J, Liu Q.. The controversial links among calorie restriction, SIRT1, and resveratrol. Free Radic Biol Med. 2011 ; 51 (2). 250-256
45. Kao CL, Chen LK, Chang YL, et al. Resveratrol protects human endothelium from H(2)O(2)-induced oxidative stress and senescence via SirT1 activation. J Atheroscler Thromb. 2010 ; 17 (9). 970-979
46. Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, Gupta M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2010 ; 298 (3). H833 - H843
47. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem. 2005 ; 280 (17). 17187-17195
48. Raval AP, Dave KR, Perez-Pinzon MA. Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab. 2006 ; 26 (9). 1141-1147